Testing effectiveness (Phase 2)Study completedNCT00946270What this trial is testingPomalidomide for Myelofibrosis PatientsWho this might be right forPolycythemia VeraThrombocythemia M.D. Anderson Cancer Center 70
Early research (Phase 1)Study completedNCT00910728What this trial is testingStudy to Assess the Safety of AZD1480 in Patients With Myeloproliferative DiseasesWho this might be right forPrimary Myelofibrosis (PMF)Post-Polycythaemia VeraEssential Thrombocythaemia Myelofibrosis AstraZeneca 65
Large-scale testing (Phase 3)Study completedNCT01969838What this trial is testingMomelotinib Versus Ruxolitinib in Subjects With MyelofibrosisWho this might be right forPrimary MyelofibrosisPost-Polycythemia Vera MyelofibrosisPost-Essential Thrombocythemia Myelofibrosis Sierra Oncology LLC - a GSK company 432
Large-scale testing (Phase 3)Study completedNCT04173494What this trial is testingMomelotinib Versus Danazol in Symptomatic and Anemic Myelofibrosis Participants (MOMENTUM)Who this might be right forPrimary MyelofibrosisPost-polycythemia Vera MyelofibrosisPost-essential Thrombocythemia Myelofibrosis Sierra Oncology LLC - a GSK company 195
Testing effectiveness (Phase 2)UnknownNCT04878003What this trial is testingStudy of KRT-232 or TL-895 in Janus Associated Kinase Inhibitor Treatment-Naïve MyelofibrosisWho this might be right forPrimary Myelofibrosis (PMF)Post-Polycythemia Vera Myelofibrosis (Post-PV-MF)Post-Essential Thrombocythemia Myelofibrosis (Post-ET-MF) Kartos Therapeutics, Inc. 52
Testing effectiveness (Phase 2)Looking for participantsNCT05835466What this trial is testingReparixin in Patients With Myelofibrosis Myeloproliferative Neoplasms Research Consortium (MPN-RC 120)Who this might be right forMyelofibrosis (PMF)Post Essential Thrombocythemia Myelofibrosis (ET-MF)Post Polycythemia Vera Related Myelofibrosis (PV-MF) Icahn School of Medicine at Mount Sinai 10
Early research (Phase 1)Ended earlyNCT01291784What this trial is testingAnti-TGF-beta Therapy in Patients With MyelofibrosisWho this might be right forMyelofibrosisPrimary MyelofibrosisPolycythemia Vera, Post-Polycythemic Myelofibrosis Phase+1 more John Mascarenhas 3
Testing effectiveness (Phase 2)UnknownNCT01298934What this trial is testingLBH589 (Panobinostat) for the Treatment of MyelofibrosisWho this might be right forPrimary MyelofibrosisPolycythemia Vera, Post-Polycythemic Myelofibrosis PhasePost-Essential Thrombocythemia Related Myelofibrosis Ronald Hoffman 22
Large-scale testing (Phase 3)UnknownNCT03662126What this trial is testingKRT-232 Versus Best Available Therapy for the Treatment of Subjects With Myelofibrosis Who Are Relapsed or Refractory to JAK Inhibitor TreatmentWho this might be right forPrimary Myelofibrosis (PMF)Post-Polycythemia Vera MF (Post-PV-MF)Post-Essential Thrombocythemia MF (Post-ET-MF) Kartos Therapeutics, Inc. 385
Large-scale testing (Phase 3)Ended earlyNCT03755518What this trial is testingA Trial of Fedratinib in Subjects With DIPSS, Intermediate or High-Risk Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis and Previously Treated With RuxolitinibWho this might be right forPrimary MyelofibrosisPost-Polycythemia Vera MyelofibrosisMyelofibrosis+1 more Celgene 38
Not applicableNot Yet RecruitingNCT06785870What this trial is testingEVAluation of Erythrocytosis PRospEctive Cohort STudyWho this might be right forErythrocytosisPolycythemiaPolycythemia Secondary+5 more Cyrus Hsia 1,500
Large-scale testing (Phase 3)Study completedNCT03952039What this trial is testingAn Efficacy and Safety Study of Fedratinib Compared to Best Available Therapy in Subjects With DIPSS-intermediate or High-risk Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis, or Post-essential Thrombocythemia Myelofibrosis and Previously Treated With RuxolitinibWho this might be right forPrimary MyelofibrosisPost-Polycythemia VeraMyelofibrosis Celgene 202
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07750574What this trial is testingFlonoltinib Maleate Oral Regimens in Patients With MyelofibrosisWho this might be right forMyelofibrosisMyelofibrosis Due to and Following Polycythemia VeraMyelofibrosis Transformation in Essential Thrombocythemia+9 more Chengdu Zenitar Biomedical Technology Co., Ltd 105
Early research (Phase 1)UnknownNCT05279001What this trial is testingA Safety and Tolerability Study of JaktinibWho this might be right forMyelofibrosis Suzhou Zelgen Biopharmaceuticals Co.,Ltd 26
Testing effectiveness (Phase 2)Ended earlyNCT01668173What this trial is testingHSP90 Inhibitor, AUY922, in Patients With Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (Post-PV MF), Post-Essential Thrombocythemia Myelofibrosis (Post-ET MF), and Refractory PV/ETWho this might be right forMyeloproliferative Neoplasms Memorial Sloan Kettering Cancer Center 7
Testing effectiveness (Phase 2)Study completedNCT02098161What this trial is testingLCL161 in Treating Patients With Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocytosis MyelofibrosisWho this might be right forPolycythemia Vera, Post-Polycythemic Myelofibrosis PhasePrimary MyelofibrosisSecondary Myelofibrosis M.D. Anderson Cancer Center 50
Large-scale testing (Phase 3)Looking for participantsNCT04655092What this trial is testingExtension Study of P1101 After Completion of Phase 2 Study in PV Patients or Phase 3 Study in ET PatientsWho this might be right forPolycythemia Vera (PV) PharmaEssentia Japan K.K. 67
Testing effectiveness (Phase 2)Study completedNCT01200498What this trial is testingStudy of SB939 in Subjects With MyelofibrosisWho this might be right forMyeloproliferative Disorders M.D. Anderson Cancer Center 23
Testing effectiveness (Phase 2)Study completedNCT01787552What this trial is testingA Phase Ib/II Dose-finding Study to Assess the Safety and Efficacy of LDE225 + INC424 in Patients With MFWho this might be right forPrimary MyelofibrosisThrombocytosisEssential Thrombocythemia+7 more Novartis Pharmaceuticals 50
Testing effectiveness (Phase 2)Study completedNCT00509899What this trial is testingOpen Label Ruxolitinib (INCB018424) in Patients With Myelofibrosis and Post Polycythemia Vera/Essential Thrombocythemia MyelofibrosisWho this might be right forMyelofibrosisPolycythemia VeraThrombocytosis Incyte Corporation 154